Capital Group Global Equity Fund (LUX) P (EUR)Register to Unlock Ratings |
Performance History | 31/08/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | - | - | - | - | 9.3 | |
+/-Cat | - | - | - | - | -0.6 | |
+/-B’mrk | - | - | - | - | -3.1 | |
Category: Global Large-Cap Blend Equity | ||||||
Category Benchmark: Morningstar Global TME NR USD |
Key Stats | ||
NAV 27/09/2024 | EUR 49.69 | |
Day Change | -0.08% | |
Morningstar Category™ | Global Large-Cap Blend Equity | |
ISIN | LU2717363043 | |
Fund Size (Mil) 27/09/2024 | USD 675.19 | |
Share Class Size (Mil) 27/09/2024 | USD 4.37 | |
Max Initial Charge | 5.25% | |
Ongoing Charge 31/07/2024 | 0.75% |
Investment Objective: Capital Group Global Equity Fund (LUX) P (EUR) |
Long-term capital growth through investment primarily in listed Equity, researched and selected on a world-wide basis. Unlisted securities may also be purchased, subject to the relevant provisions of the "General Investment Guidelines and Restrictions". |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Philip Winston 22/01/2020 | ||
William Robbins 22/01/2020 | ||
Click here to see others | ||
Inception Date 16/08/2021 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
MSCI World NR USD | Morningstar Global TME NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Capital Group Global Equity Fund (LUX) P (EUR) | 31/08/2024 |
|
|
Top 5 Holdings | Sector | % |
Novo Nordisk AS Class B | Healthcare | 2.98 |
Broadcom Inc | Technology | 2.81 |
Microsoft Corp | Technology | 2.29 |
AstraZeneca PLC | Healthcare | 2.16 |
Apple Inc | Technology | 2.14 |
Increase Decrease New since last portfolio | ||
Capital Group Global Equity Fund (LUX) P (EUR) |